English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

To the Editor:In their prospective cohort study of 87 patients with cerebral cavernous malformations (CCMs), Schneble et al1 observed 11 CCM-related bleeds in 9 patients without antithrombotic treatments, whereas there was no bleeding event in 16 patients on antithrombotic treatment. For their analyses, the authors grouped together patients using antiplatelet drugs (n=11) and warfarin (n=5), although these drugs are associated with substantially different risks of intracranial bleeding in the general population, and although the 5 patients on warfarin (31% of the subgroup receiving antithrombotic therapy) contributed disproportionally to patient-years (68%) and lesion-years …

stroke

Letter by Kurnik et al Regarding Article, “Antithrombotic Therapy and Bleeding Risk in a Prospective Cohort Study of Patients With Cerebral Cavernous Malformations”